Cargando…
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
INTRODUCTION: We have previously demonstrated that endoxifen is the most important tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα). However, the relevance of ERβ in mediating endoxifen action has...
Autores principales: | Wu, Xianglin, Subramaniam, Malayannan, Grygo, Sarah B, Sun, Zhifu, Negron, Vivian, Lingle, Wilma L, Goetz, Matthew P, Ingle, James N, Spelsberg, Thomas C, Hawse, John R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219188/ https://www.ncbi.nlm.nih.gov/pubmed/21392396 http://dx.doi.org/10.1186/bcr2844 |
Ejemplares similares
-
Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens
por: Hawse, John R., et al.
Publicado: (2013) -
SUN-LB135 Estrogen Receptor Beta Inhibits NFkB Signaling to Inhibit Triple Negative Breast Cancer
por: Aspros, Kirsten, et al.
Publicado: (2020) -
The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton
por: Gingery, Anne, et al.
Publicado: (2014) -
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020) -
Disruption of estrogen receptor beta’s DNA binding domain impairs its tumor suppressive effects in triple negative breast cancer
por: Aspros, Kirsten G. M., et al.
Publicado: (2023)